Vyant Bio, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q3 FY2021 As of Aug 21, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018
Assets
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable
Earn-Out from siParadigm, current portion
Excess Consideration Note
Trade accounts and other receivables
Inventory
Patent held for sale
Other current assets
Prepaid expenses and other current assets
Assets of discontinuing operations – current
Total current assets
FIXED ASSETS, net of accumulated depreciation
Non-current assets:
Fixed assets, net
Operating lease, right-of-use asset
Restricted cash
Patents and other intangible assets, net of accumulated amortization
Earn-Out from siParadigm, less current portion
Intangible assets, net
Investment in joint venture
Goodwill
Other
Total other assets
Long-term prepaid expenses and other assets
Assets of discontinuing operations – non-current
Total non-current assets

Total Assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses
Accounts payable
Accrued expenses
Deferred revenue
Obligations under operating leases, current portion
Obligation under finance lease, current portion
Obligations under finance leases, current portion
Line of credit
Term note
Convertible note, net
Note payable, net
Advance, current
NDX
siParadigm
Biosciences
Buyer
Total advance, current

Other derivatives
Other current liabilities
Other current liabilities - discontinued operations
Liabilities of discontinuing operations – current
Total current liabilities

Obligations under operating leases, less current portion
Obligations under finance leases, less current portion
Advance from siParadigm, less current portion
siParadigm
Total advance from siParadigm, less current portion
Deferred rent payable and other
Deferred revenue, long-term
Share-settlement obligation derivative
Warrant liability
Accrued interest
Long-term debt
Liabilities of discontinuing operations – non-current
Total Liabilities
Temporary Equity
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Total Temporary Equity
Stockholders’ Equity
Preferred stock, authorized 9,764 shares $ 0.0001 par value, 0 shares issued and outstanding as of December 31, 2022 and 2021
Common stock, authorized 100,000 shares, $0.0001 par value, 5,922 and 5,798 shares issued and outstanding as of December 31, 2022 and 2021, respectively
Additional paid-in capital
Accumulated comprehensive loss
Accumulated deficit
Total Stockholders’ equity (deficit)
Total Common Stockholders’ Equity
Total Liabilities and Stockholders’ Equity

Comments